TNF Inhibitor denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies TNF Inhibitors on Medical-Necessity Grounds

UnitedHealthcare (UHC) requires that a TNF inhibitor (such as adalimumab, etanercept, infliximab, certolizumab, or golimumab) be prescribed for a condition for which the drug is FDA-approved, that the condition has been confirmed by a qualified specialist, and that conventional first-line therapies have been tried and have failed or are medically contraindicated. When documentation is incomplete — or when the insurer's clinical reviewer cannot verify that these conditions are met from the submitted records — a medical-necessity denial follows.

## Why This Denial Is Appealable

Medical-necessity denials are among the most commonly overturned on appeal when the clinical record is organized and complete. UHC must comply with the ACA §2719 external-review framework and, for employer self-funded plans, ERISA §503's full-and-fair review requirements. You have the right to an internal appeal and then an independent external review by a state-certified or federally approved Independent Review Organization (IRO).

## Federal Appeal Framework

• Internal appeal deadline: You generally have 180 days from the denial notice to file an internal appeal with UHC.
• External review window: After exhausting internal appeal (or if UHC misses its decision deadline), you may request external review — typically within four months of the final internal denial.
• Expedited option: If your condition is urgent or you are currently on the medication, request expedited review; UHC must respond within 72 hours internally and the IRO within 72 hours externally.

## Documentation to Gather

1. Diagnosis confirmation — specialist visit notes establishing the specific diagnosis (e.g., rheumatoid arthritis, plaque psoriasis, Crohn's disease, ankylosing spondylitis, or other approved indication), including disease-activity assessments recorded in the chart. 2. Prior-treatment history — pharmacy records, provider notes, and EOBs showing dates started, doses tried, duration, and documented reason for discontinuation (inadequate response, intolerance, contraindication) for each prior therapy. 3. Clinical severity documentation — chart entries, validated scoring instruments, and specialist assessments demonstrating current disease severity and impact on daily functioning. 4. Prescriber medical-necessity letter — a detailed letter from the treating physician explaining why the prescribed TNF inhibitor is necessary for this patient, why prior therapies were insufficient, and how the patient meets the criteria in both the FDA-approved labeling and UHC's published coverage policy. 5. Applicable guideline support — a reference to the relevant specialty guideline organization (e.g., ACR for rheumatologic indications, AAD for dermatologic indications, ACG for GI indications) supporting TNF inhibitor use at this stage of disease.

## Criteria-Mapping Structure

For each requirement listed in UHC's current published medical policy for TNF inhibitors, pull the exact chart fact that satisfies it and place them side by side in your appeal letter:

| Policy Requirement (from UHC's published policy) | Chart Evidence (with date and source note) | |---|---| | Confirmed diagnosis of covered indication | Specialist note dated ___ | | Inadequate response to required prior therapies | Pharmacy records + progress notes dated ___ | | Disease severity meets coverage threshold | Validated score in chart, date ___ | | Prescribed by or in consultation with appropriate specialist | Treating physician credentials, NPI ___ |

Review the FDA-approved prescribing information and UHC's current published coverage policy to confirm every eligibility criterion, because policy details change and the exact thresholds must come from those primary sources.